Overcoming a "Probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: Study of 100 sera and review of the literature

Nicola Bizzaro, Giovanni Covini, Floriano Rosina, Paolo Muratori, Elio Tonutti, Danilo Villalta, Fiorenza Pesente, Maria Grazia Alessio, Marilina Tampoia, Antonio Antico, Stefan Platzgummer, Brunetta Porcelli, Lucia Terzuoli, Marco Liguori, Danila Bassetti, Ignazio Brusca, Piero L. Almasio, Giuseppe Tarantino, Chiara Bonaguri, Paolo AgostinisElena Bredi, Renato Tozzoli, Pietro Invernizzi, Carlo Selmi

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Serum anti-mitochondrial antibodies (AMA) are the serological hallmark of primary biliary cirrhosis (PBC), yet up to 15% of PBC sera are AMA negative at routine indirect immunofluorescence (IIF) while being referred to as "probable" cases. The diagnostic role of PBC-specific antinuclear antibodies (ANA) remains to be determined. We will report herein data on the accuracy of new laboratory tools for AMA and PBC-specific ANA in a large series of PBC sera that were AMA-negative at IIF. We will also provide a discussion of the history and current status of AMA detection methods. We included IIF AMA-negative PBC sera (n=100) and sera from patients with other chronic liver diseases (n=104) that had been independently tested for IIF AMA and ANA; sera were blindly tested with an ELISA PBC screening test including two ANA (gp210, sp100) and a triple (pMIT3) AMA recombinant antigens. Among IIF AMA-negative sera, 43/100 (43%) manifested reactivity using the PBC screening test. The same test was positive for 6/104 (5.8%) control sera. IIF AMA-negative/PBC screen-positive sera reacted against pMIT3 (11/43), gp210 (8/43), Sp100 (17/43), both pMIT3 and gp210 (1/43), or both pMIT3 and Sp100 (6/43). Concordance rates between the ANA pattern on HEp-2 cells and specific Sp100 and gp210 ELISA results in AMA-negative subjects were 92% for nuclear dots and Sp100 and 99% for nuclear rim and gp210. Our data confirm the hypothesis that a substantial part of IIF AMA-negative (formerly coined "probable") PBC cases manifest disease-specific autoantibodies when tested using newly available tools and thus overcome the previously suggested diagnostic classification. As suggested by the recent literature, we are convinced that the proportion of AMA-negative PBC cases will be significantly minimized by the use of new laboratory methods and recombinant antigens.

Original languageEnglish (US)
Pages (from-to)288-297
Number of pages10
JournalClinical Reviews in Allergy and Immunology
Volume42
Issue number3
DOIs
StatePublished - Jun 2012
Externally publishedYes

Fingerprint

Biliary Liver Cirrhosis
Anti-Idiotypic Antibodies
Antibodies
Indirect Fluorescent Antibody Technique
Serum
Antinuclear Antibodies
Enzyme-Linked Immunosorbent Assay
Antigens
Autoantibodies
Liver Diseases
Chronic Disease

Keywords

  • Autoimmune cholangitis
  • Diagnostic accuracy
  • Nuclear dots
  • Recombinant antigens
  • Rim like

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Overcoming a "Probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis : Study of 100 sera and review of the literature. / Bizzaro, Nicola; Covini, Giovanni; Rosina, Floriano; Muratori, Paolo; Tonutti, Elio; Villalta, Danilo; Pesente, Fiorenza; Alessio, Maria Grazia; Tampoia, Marilina; Antico, Antonio; Platzgummer, Stefan; Porcelli, Brunetta; Terzuoli, Lucia; Liguori, Marco; Bassetti, Danila; Brusca, Ignazio; Almasio, Piero L.; Tarantino, Giuseppe; Bonaguri, Chiara; Agostinis, Paolo; Bredi, Elena; Tozzoli, Renato; Invernizzi, Pietro; Selmi, Carlo.

In: Clinical Reviews in Allergy and Immunology, Vol. 42, No. 3, 06.2012, p. 288-297.

Research output: Contribution to journalArticle

Bizzaro, N, Covini, G, Rosina, F, Muratori, P, Tonutti, E, Villalta, D, Pesente, F, Alessio, MG, Tampoia, M, Antico, A, Platzgummer, S, Porcelli, B, Terzuoli, L, Liguori, M, Bassetti, D, Brusca, I, Almasio, PL, Tarantino, G, Bonaguri, C, Agostinis, P, Bredi, E, Tozzoli, R, Invernizzi, P & Selmi, C 2012, 'Overcoming a "Probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: Study of 100 sera and review of the literature', Clinical Reviews in Allergy and Immunology, vol. 42, no. 3, pp. 288-297. https://doi.org/10.1007/s12016-010-8234-y
Bizzaro, Nicola ; Covini, Giovanni ; Rosina, Floriano ; Muratori, Paolo ; Tonutti, Elio ; Villalta, Danilo ; Pesente, Fiorenza ; Alessio, Maria Grazia ; Tampoia, Marilina ; Antico, Antonio ; Platzgummer, Stefan ; Porcelli, Brunetta ; Terzuoli, Lucia ; Liguori, Marco ; Bassetti, Danila ; Brusca, Ignazio ; Almasio, Piero L. ; Tarantino, Giuseppe ; Bonaguri, Chiara ; Agostinis, Paolo ; Bredi, Elena ; Tozzoli, Renato ; Invernizzi, Pietro ; Selmi, Carlo. / Overcoming a "Probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis : Study of 100 sera and review of the literature. In: Clinical Reviews in Allergy and Immunology. 2012 ; Vol. 42, No. 3. pp. 288-297.
@article{86edf8e65cc74332a336551a9e705f4a,
title = "Overcoming a {"}Probable{"} diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: Study of 100 sera and review of the literature",
abstract = "Serum anti-mitochondrial antibodies (AMA) are the serological hallmark of primary biliary cirrhosis (PBC), yet up to 15{\%} of PBC sera are AMA negative at routine indirect immunofluorescence (IIF) while being referred to as {"}probable{"} cases. The diagnostic role of PBC-specific antinuclear antibodies (ANA) remains to be determined. We will report herein data on the accuracy of new laboratory tools for AMA and PBC-specific ANA in a large series of PBC sera that were AMA-negative at IIF. We will also provide a discussion of the history and current status of AMA detection methods. We included IIF AMA-negative PBC sera (n=100) and sera from patients with other chronic liver diseases (n=104) that had been independently tested for IIF AMA and ANA; sera were blindly tested with an ELISA PBC screening test including two ANA (gp210, sp100) and a triple (pMIT3) AMA recombinant antigens. Among IIF AMA-negative sera, 43/100 (43{\%}) manifested reactivity using the PBC screening test. The same test was positive for 6/104 (5.8{\%}) control sera. IIF AMA-negative/PBC screen-positive sera reacted against pMIT3 (11/43), gp210 (8/43), Sp100 (17/43), both pMIT3 and gp210 (1/43), or both pMIT3 and Sp100 (6/43). Concordance rates between the ANA pattern on HEp-2 cells and specific Sp100 and gp210 ELISA results in AMA-negative subjects were 92{\%} for nuclear dots and Sp100 and 99{\%} for nuclear rim and gp210. Our data confirm the hypothesis that a substantial part of IIF AMA-negative (formerly coined {"}probable{"}) PBC cases manifest disease-specific autoantibodies when tested using newly available tools and thus overcome the previously suggested diagnostic classification. As suggested by the recent literature, we are convinced that the proportion of AMA-negative PBC cases will be significantly minimized by the use of new laboratory methods and recombinant antigens.",
keywords = "Autoimmune cholangitis, Diagnostic accuracy, Nuclear dots, Recombinant antigens, Rim like",
author = "Nicola Bizzaro and Giovanni Covini and Floriano Rosina and Paolo Muratori and Elio Tonutti and Danilo Villalta and Fiorenza Pesente and Alessio, {Maria Grazia} and Marilina Tampoia and Antonio Antico and Stefan Platzgummer and Brunetta Porcelli and Lucia Terzuoli and Marco Liguori and Danila Bassetti and Ignazio Brusca and Almasio, {Piero L.} and Giuseppe Tarantino and Chiara Bonaguri and Paolo Agostinis and Elena Bredi and Renato Tozzoli and Pietro Invernizzi and Carlo Selmi",
year = "2012",
month = "6",
doi = "10.1007/s12016-010-8234-y",
language = "English (US)",
volume = "42",
pages = "288--297",
journal = "Clinical Reviews in Allergy and Immunology",
issn = "1080-0549",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Overcoming a "Probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis

T2 - Study of 100 sera and review of the literature

AU - Bizzaro, Nicola

AU - Covini, Giovanni

AU - Rosina, Floriano

AU - Muratori, Paolo

AU - Tonutti, Elio

AU - Villalta, Danilo

AU - Pesente, Fiorenza

AU - Alessio, Maria Grazia

AU - Tampoia, Marilina

AU - Antico, Antonio

AU - Platzgummer, Stefan

AU - Porcelli, Brunetta

AU - Terzuoli, Lucia

AU - Liguori, Marco

AU - Bassetti, Danila

AU - Brusca, Ignazio

AU - Almasio, Piero L.

AU - Tarantino, Giuseppe

AU - Bonaguri, Chiara

AU - Agostinis, Paolo

AU - Bredi, Elena

AU - Tozzoli, Renato

AU - Invernizzi, Pietro

AU - Selmi, Carlo

PY - 2012/6

Y1 - 2012/6

N2 - Serum anti-mitochondrial antibodies (AMA) are the serological hallmark of primary biliary cirrhosis (PBC), yet up to 15% of PBC sera are AMA negative at routine indirect immunofluorescence (IIF) while being referred to as "probable" cases. The diagnostic role of PBC-specific antinuclear antibodies (ANA) remains to be determined. We will report herein data on the accuracy of new laboratory tools for AMA and PBC-specific ANA in a large series of PBC sera that were AMA-negative at IIF. We will also provide a discussion of the history and current status of AMA detection methods. We included IIF AMA-negative PBC sera (n=100) and sera from patients with other chronic liver diseases (n=104) that had been independently tested for IIF AMA and ANA; sera were blindly tested with an ELISA PBC screening test including two ANA (gp210, sp100) and a triple (pMIT3) AMA recombinant antigens. Among IIF AMA-negative sera, 43/100 (43%) manifested reactivity using the PBC screening test. The same test was positive for 6/104 (5.8%) control sera. IIF AMA-negative/PBC screen-positive sera reacted against pMIT3 (11/43), gp210 (8/43), Sp100 (17/43), both pMIT3 and gp210 (1/43), or both pMIT3 and Sp100 (6/43). Concordance rates between the ANA pattern on HEp-2 cells and specific Sp100 and gp210 ELISA results in AMA-negative subjects were 92% for nuclear dots and Sp100 and 99% for nuclear rim and gp210. Our data confirm the hypothesis that a substantial part of IIF AMA-negative (formerly coined "probable") PBC cases manifest disease-specific autoantibodies when tested using newly available tools and thus overcome the previously suggested diagnostic classification. As suggested by the recent literature, we are convinced that the proportion of AMA-negative PBC cases will be significantly minimized by the use of new laboratory methods and recombinant antigens.

AB - Serum anti-mitochondrial antibodies (AMA) are the serological hallmark of primary biliary cirrhosis (PBC), yet up to 15% of PBC sera are AMA negative at routine indirect immunofluorescence (IIF) while being referred to as "probable" cases. The diagnostic role of PBC-specific antinuclear antibodies (ANA) remains to be determined. We will report herein data on the accuracy of new laboratory tools for AMA and PBC-specific ANA in a large series of PBC sera that were AMA-negative at IIF. We will also provide a discussion of the history and current status of AMA detection methods. We included IIF AMA-negative PBC sera (n=100) and sera from patients with other chronic liver diseases (n=104) that had been independently tested for IIF AMA and ANA; sera were blindly tested with an ELISA PBC screening test including two ANA (gp210, sp100) and a triple (pMIT3) AMA recombinant antigens. Among IIF AMA-negative sera, 43/100 (43%) manifested reactivity using the PBC screening test. The same test was positive for 6/104 (5.8%) control sera. IIF AMA-negative/PBC screen-positive sera reacted against pMIT3 (11/43), gp210 (8/43), Sp100 (17/43), both pMIT3 and gp210 (1/43), or both pMIT3 and Sp100 (6/43). Concordance rates between the ANA pattern on HEp-2 cells and specific Sp100 and gp210 ELISA results in AMA-negative subjects were 92% for nuclear dots and Sp100 and 99% for nuclear rim and gp210. Our data confirm the hypothesis that a substantial part of IIF AMA-negative (formerly coined "probable") PBC cases manifest disease-specific autoantibodies when tested using newly available tools and thus overcome the previously suggested diagnostic classification. As suggested by the recent literature, we are convinced that the proportion of AMA-negative PBC cases will be significantly minimized by the use of new laboratory methods and recombinant antigens.

KW - Autoimmune cholangitis

KW - Diagnostic accuracy

KW - Nuclear dots

KW - Recombinant antigens

KW - Rim like

UR - http://www.scopus.com/inward/record.url?scp=84865258466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865258466&partnerID=8YFLogxK

U2 - 10.1007/s12016-010-8234-y

DO - 10.1007/s12016-010-8234-y

M3 - Article

C2 - 21188646

AN - SCOPUS:84865258466

VL - 42

SP - 288

EP - 297

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

SN - 1080-0549

IS - 3

ER -